Maze Therapeutics

This #InternationalWomensDay, we’re celebrating the women of Maze whose ideas, leadership and dedication help move our science and mission forward every day. We’re proud to foster a workplace where women are supported, empowered and able to thrive. Because when women rise, we all go further together.

Our CEO Jason Coloma, Ph.D., will participate in a fireside chat at the 46th Annual TD Cowen Health Care Conference on Wednesday, March 4th at 10:30 a.m. ET in Boston. A live webcast of the event will be available in the Investors section of our website and archived for 60 days following the presentation. More info here: ir.mazetx.com/news-releases/…

In recognition of #BlackHistoryMonth, we welcomed Maze patient advisory committee member and #APOL1 #kidneydisease warrior Sharron Rouse for a powerful discussion on how APOL1 advocacy groups can better support patients, highlighting the importance of education, community, and patient voices. Hope begins with awareness and strong advocacy can transform the patient journey by empowering individuals, strengthening communities, and paving the way for meaningful change. Learn more about Sharron's patient advocacy group @kkidneys here: kindnessforkidneys.org

On the Let’s Talk About That podcast, our CEO Jason Coloma sat down with @anirvan0419 to reflect on Maze’s journey from its earliest days through its IPO. He also shared how Maze anticipates growing over the next several years and continuing to build for durable impact through its #precisionmedicine approach. Listen here: open.spotify.com/episode/7dCJGG…

We look forward to participating in the @GuggenheimPtnrs Emerging Outlook: Biotech Summit 2026 next week. A live webcast of the event will be available in the Investors section of our website and archived for 30 days following the presentation. Read more: ir.mazetx.com/news-releases/…

⚕️@MazeInBiotech is committed to developing breakthrough precision medicines for patients living with renal, cardiovascular and related metabolic diseases. 🎊 Proud to be your exchange partner, $MAZE! #NasdaqListed

One year ago, Maze took a major step forward with our debut as a public company. This week, we celebrated that milestone and our subsequent success, ringing the @NasdaqExchange opening bell in honor of our one-year #IPOanniversary. We’re proud of what we’ve accomplished together and energized by what’s ahead as we continue to execute in dedication to transforming the lives of patients living with kidney and metabolic diseases. $MAZE

At #JPM26? Join us this morning at 8:15 a.m. PT for our presentation.

We’re looking forward to kicking off the new year at #JPM26. CEO Jason Coloma, Ph.D., will present on Monday, January 12 at 8:15 a.m. PT. A live webcast of the event will be available in the Investors section of our website and archived for 30 days following the presentation. ir.mazetx.com/news-releases/…

As we close out 2025, we’re taking a moment to reflect on what has truly made it meaningful. This year was filled with important milestones, deeper partnerships with the patient community, and continued progress driven by science. We’re grateful to everyone who has been part of this journey and excited for what’s ahead in 2026!

Our president, head of research and development, and chief medical officer Harold Bernstein, M.D., Ph.D., recently shared the Maze story at the BioScience Forum, a monthly gathering for the biotech community in the San Francisco Bay Area. We appreciated the opportunity to connect with peers and discuss Maze’s mission and scientific approach, including how our Compass platform leverages variant functionalization to design #precisionmedicines that account for the genetic drivers of disease. biosf.org

On #PKUAwarenessDay, Maze supports @NPKUA_info, PKU patients, and families. We honor the #phenylketonuria community and recognize the strength, resilience, and advocacy of individuals and families navigating this rare metabolic disorder. At Maze, we’re dedicated to advancing meaningful options for people living with PKU through our investigational program, MZE782, an oral, small-molecule targeting the solute transporter SLC6A19, designed with the potential to deliver a best-in-class therapy for individuals with PKU. Learn more about PKU and ways to support the community through @NPKUA_info here: npkua.org

We enjoyed sharing Maze’s progress and connecting with the kidney community at @ASNKidney's #KidneyWk this year. It was inspiring to join those who share a commitment to advancing care for people living with #kidneydisease. While in the area, we also participated in the @nkf Houston #KidneyWalk, joining patients, families, and supporters to raise awareness. We’re grateful for the meaningful conversations and energized by the shared dedication across the field.

We reported financial results for the third quarter ended September 30, 2025, highlighting recent progress and business updates. Read the full announcement here: ir.mazetx.com/news-releases/…

We're excited to be at this year’s @ASNKidney’s #KidneyWk! This week, we will present additional pharmacokinetic data from our Phase 1 clinical trial of MZE782, research supporting inhibition of SLC6A19 to slow disease progression in #chronickidneydisease and data supporting the scientific foundation and therapeutic rationale for MZE829. Read more: ir.mazetx.com/news-releases/…

We’re looking forward to connecting at several upcoming investor conferences, where members of the Maze leadership team will be participating in fireside chats. See today’s announcement for details: ir.mazetx.com/news-releases/…

Our CEO Jason Coloma joined @SullyCNBC on @CNBC’s @PowerLunch to discuss Maze’s recent progress and how we’re translating human genetics into new therapies across our pipeline. Chronic kidney disease remains a devastating condition with limited treatment options, affecting millions of patients and families worldwide. At Maze, we’re committed to advancing novel #smallmolecule #precisionmedicines designed to address the underlying drivers of #kidneydisease and metabolic disorders in meaningful ways. Watch the full interview: cnbc.com/video/2025/10/…

Welcome Hervé Hoppenot as Chairman of our Board of Directors, succeeding Charles Homcy, M.D., who will remain on the Board. Hervé’s decades of experience will be invaluable as we approach major milestones in 2026. ir.mazetx.com/news-releases/…

Walking alongside patients, caregivers, and advocates was a powerful reminder of why we’re committed to advancing science and developing potential therapies that can make a difference in kidney health, including conditions such as #APOL1-mediated kidney disease.

We recently joined the Tampa Bay #KidneyWalk, hosted by the @nkf, to help raise awareness and support for the millions of people impacted by #kidneydisease.